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Abstract
Whereas only neurologists can “rule in” functional neurologic dis-
orders (FNDs)—using physical signs and semiologic features—
their role in follow-up care remains debated. We outlined the
arguments for and against a neurologist’s primary role in both
assessing and managing FNDs. Favorable arguments include the
following: (1) FND presents neurologically, and thus, only neu-
rologists can ascertain the etiology of new neurologic deficits
appearing on follow-up, and (2) neurologic encounters facilitate
acceptance of diagnosis and enhance treatment engagement.
Counter arguments include the following: (1) FND is a Diagnostic
and Statistical Manual of Mental Disorders, 5th Edition codified
psychiatric disorder with largely psychiatric treatments, and (2)
neurologists can reassess patients if new neurologic symptoms
develop without playing a primary follow-up role. Although more
research is needed to clarify optimal approaches, neurologic ex-
pertise could be leveraged for diagnostic and coordinating roles if
the pool of neurologists, psychiatrists, psychotherapists, physical
and occupational therapists, and other allied clinicians trained in the interdisciplinary care of
FNDs is substantially increased.
Functional neurologic disorders (FNDs) are a prevalent source of neurologic disability.
Previously termed “psychogenic,” the FND diagnosis no longer requires the presence of
a psychological stressor per Diagnostic and Statistical Manual of Mental Disorders, 5th
Edition (DSM-5) criteria, emphasizing the importance of phenotype. Diagnostic delays and
a scarce supply of clinicians knowledgeable in these disorders magnify personal and societal
costs. At the AAN’s 2018 Controversies in Neurology Plenary Session, Drs. Perez and Haller
acknowledged that the diagnostic acumen rests on the neurologist but offered disparate
perspectives on the neurologist’s role in the management of FNDs. The arguments outlined
below, discussed in part during a subsequent Neurology® podcast with Dr. Espay, further
advance this important dialogue.
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FND, a condition at the interface of neurology and psychiatry,
necessitates engagement from the neurologist throughout di-
agnostic assessment and longitudinal management. The
arguments for this include the following (1) FND is a “rule-in”
diagnosis based on neurologic examination of signs and
semiologic features, making neurologic expertise critical.1
Patients can also present with 1 symptom constellation and
subsequently develop new symptoms emphasizing the im-
portance of longitudinal neurologic assessments. (2) Neuro-
logic encounters are primed to catalyze and support treatment
across all phases of care. Neurologists are encouraged to share
with patients their examination signs supporting the FND
diagnosis,2 and delivery of the diagnosis by a neurologist is
among the first and most important treatment steps.3 Fur-
thermore, neurology follow-up visits are primed to explore
predisposing and perpetuating factors such as unhelpful ill-
ness beliefs and maladaptive avoidance behaviors, which can
impede treatment and may not be initially identifiable. (3)
Although it is helpful to frame FND as a “software problem”
to highlight recoverability, there is emerging quantitative
structural neuroimaging data suggesting that FND may be
both a “hardware and software” problem further blurring the
lines between neurologic and psychiatric frameworks.4 (4)
Patients with FNDs can show marked improvements, which
make working with this population satisfying. There is also
a vibrant international community of FND clinicians and
researchers, many of whom are prominent neurologists
highlighting that work in this area can be professionally re-
warding. Nonetheless, there remains a need to think con-
structively regarding how to “close the divide” between
neurology and psychiatry for neuropsychiatrically complex
patients.5 The comprehensive assessment and management
of FNDs requires an interdisciplinary, team-based approach
and the development of a subset of physicians with shared
neurology-psychiatry expertise.
Andrea L. Haller, MD
FNDs are psychiatric disorders with diagnostic criteria cod-
ified in the DSM-5. Signs and symptoms in FNDs are in-
consistent with any known medical or neurologic disorder.
When treating a patient with FNDs, the first step is a thor-
ough evaluation to rule out the possibility that an organic
neurologic disorder is the etiology of the patient’s symptoms.
Next, the neurologist explains the diagnosis (validating
symptoms) before providing reassurance that appropriate
treatment is available and referring the patient to that
treatment. Treatment of FNDs is non-neurologic. Cogni-
tive behavioral therapy is a primary treatment, but other
modalities are also used. Should patients with FNDs de-
velop new neurologic symptoms over the course of treat-
ment, reassessment and reassurance by the neurologist is
appropriate.
Despite research-related functional and structural neuro-
imaging abnormalities, FND treatments are psychiatric, not
neurologic. Similar neuroimaging abnormalities are identi-
fied in other psychiatric conditions (e.g., major depression
and posttraumatic stress disorder). Where is the line drawn?
Regarding closure of “the great divide,” I would ask are
psychiatrists going to start managing Parkinson disease,
stroke, or multiple sclerosis? I no more believe this is ap-
propriate than I feel that neurologists are adequately trained
to treat patients with FNDs.
Neurology exploded in breadth and depth during the past 2
decades, and during this period, resident training time was
cut. There is more to learn and less time to learn it. Neu-
rologists are not trained in the treatments of other specialties,
and there are more demands on their time than ever before.6
To add the responsibility of managing this psychiatric dis-
order would be illogically burdensome. Patients with FNDs
require time-intensive treatment that neurologists are not
trained to provide. They deserve to be seen by practitioners
skilled in the techniques with proven efficacy.
Next steps
Given the above discussions, continued interdisciplinary
dialogue and large-scale clinical trials are needed to in-
vestigate, identify, and disseminate good evidence-based
practices across providers involved in the assessment and
management of FNDs. In our opinion, as awareness, pro-
vider expertise, and funding opportunities grow, it is likely
that community neurologists may play a critically important
role in the early diagnosis of patients with FNDs, while
management and longitudinal follow-up (particularly for the
most complex patients) may occur at academic medical
centers within subspecialty treatment programs using an
FND, a condition at the interface of
neurology and psychiatry,
necessitates engagement from the
neurologist throughout diagnostic
assessment and longitudinal
management. (D. L. Perez)
Despite research-related functional
and structural neuroimaging
abnormalities, FND treatments are
psychiatric, not neurologic. (A. L. Haller)
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interdisciplinary approach that actively engages neurolo-
gists, psychiatrists, psychologists, social workers, physical
and occupational therapists, and other allied clinicians as
needed to develop a patient-centered, individualized treat-
ment plan. The physician subspecialist guiding the treat-
ment plan for patients will likely require both neurologic
diagnostic expertise and neuropsychiatric proficiency. Un-
fortunately, there are multiple gaps in both clinical and re-
search arenas that currently limit the practical execution of
this promising yet challenging perspective, mostly notably
minimal training across the clinical neurosciences in the
assessment and management of FNDs and reduced in-
vestment in increasing the pool of allied health care pro-
fessionals. Education and increased public awareness efforts
are also sorely needed to support the development of ef-
fective treatments for patients with FNDs.
Conclusion
Although stemming from complex neurobio-psycho-social
influences, FND manifests neurologically. Only neurologists
(or neuropsychiatrists) are trained to assess the extent to
which features are inconsistent and incongruent with the
broad spectrum of other neurologic disorders to establish
a clinically definite FND diagnosis.7 Nonetheless, there are
severe constraints, including limited access to neurologists
andmental health professions. Physiotherapy and psychological-
based treatments allow neurologists to deploy these strategies
for FND treatment, adopting a collaborative role in the in-
terdisciplinary management. More research is needed to in-
vestigate optimal clinical practices for the longitudinal
treatment of patients with FNDs.
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